Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

Heinz Ludwig, Thomas Melchardt (Co-author), Siegfried Sormann, Martin Schreder, Johannes Andel, Bernd Hartmann, Christoph Tinchon, Niklas Zojer, Eberhard Gunsilius, Klaus Podar, Alexander Egle (Co-author), Wolfgang Willenbacher, Ewald Wöll, Reinhard Ruckser, Boris Bozic, Maria-Theresa Krauth, Andreas Petzer, Clemens Schmitt, Sigrid Machherndl-Spandl, Hermine AgisMichael Fillitz, Song-Yau Wang, August Zabernigg, Stefan Knop (Co-author), Bruno Paiva, Richard Greil (Last author)

Research output: Contribution to journalLetter to the editorpeer-review

Abstract

Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.

Original languageEnglish
Pages (from-to)1008-1011
Number of pages4
JournalAMERICAN JOURNAL OF HEMATOLOGY
Volume99
Issue number5
Early online date29 Feb 2024
DOIs
Publication statusPublished - May 2024

Keywords

  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Dexamethasone/therapeutic use
  • Humans
  • Induction Chemotherapy
  • Lenalidomide/therapeutic use
  • Multiple Myeloma/diagnosis
  • Dexamethasone
  • Lenalidomide

Fingerprint

Dive into the research topics of 'Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this